
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : MG4101
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
AlloNK® + Rituximab Safety & Efficacy In Relapsing B-Cell Dependent Rheumatologic Diseases
Details : MG4101 is a drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Arthritis, Rheumatoid.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 25, 2025
Lead Product(s) : MG4101
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Details : GCC2005 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lymphoma, T-Cell.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
November 21, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : AB-101
Therapeutic Area : Immunology
Study Phase : Phase I
Recipient : IRIS Research and Development, LLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AB-101 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Arthritis, Rheumatoid.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 03, 2024
Lead Product(s) : AB-101
Therapeutic Area : Immunology
Highest Development Status : Phase I
Recipient : IRIS Research and Development, LLC
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : AB-101,Acimtamig,Cyclophosphamide
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Jefferies
Deal Size : $167.0 million
Deal Type : Public Offering
Artiva upsizes IPO to $167 million as NK cell therapy biotech heads to Nasdaq
Details : The net proceeds will be used to fund the clinical development of the company's lead product AlloNK (AB-101), which is being evaluated for the treatment of r/r Hodgkin Lymphoma.
Product Name : AlloNK
Product Type : Miscellaneous
Upfront Cash : Undisclosed
July 18, 2024
Lead Product(s) : AB-101,Acimtamig,Cyclophosphamide
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Jefferies
Deal Size : $167.0 million
Deal Type : Public Offering

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : AB-101,Cyclophosphamide,Rituximab
Therapeutic Area : Nephrology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Artiva Biotherapeutics Receives FDA Fast Track Designation for AlloNK® in Lupus Nephritis
Details : AlloNK (AB-101) is an allogeneic NK cell therapy designed to enhance antibody-dependent cellular cytotoxicity in combination with rituximab or obinutuzumab for treating lupus nephritis.
Product Name : AlloNK
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 22, 2024
Lead Product(s) : AB-101,Cyclophosphamide,Rituximab
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : AB-101
Therapeutic Area : Nephrology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AB-101 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lupus Nephritis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 20, 2024
Lead Product(s) : AB-101
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : AB-101,Rituximab
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AlloNK (AB-101) is a non-genetically modified, cord blood-derived, allogeneic, cryopreserved, ADCC-enhancing NK cell therapy candidate for use in combination with Combination with Rituximab in Lupus Nephritis.
Product Name : AlloNK
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 16, 2023
Lead Product(s) : AB-101,Rituximab
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Phase 2 Study of AFM13 in Combination with AB-101 in Subjects with R/R HL and CD30+ PTCL
Details : AFM13 is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hodgkin Disease.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
June 01, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Acimtamig,AB-101
Therapeutic Area : Oncology
Study Phase : IND Enabling
Recipient : Affimed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AFM13 is a first-in-class innate cell engager (ICE®) that uniquely leverags the power of the innate immune system by engaging and activating natural killer (NK) cells and macrophages to destroy CD30-positive hematologic tumors.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
May 23, 2023
Lead Product(s) : Acimtamig,AB-101
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Recipient : Affimed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : AB-201
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AB-201 is a Protein drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
January 10, 2023
Lead Product(s) : AB-201
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
